By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
CytoDyn (CYDY) Release: Patients Approach Two Years Of Complete HIV Viral Load Suppression In Phase IIb PRO 140 Monotherapy Extension Study 8/23/2016 7:56:21 AM
CytoDyn (CYDY) Announces Investment Community Conference Call For August 19, 2016 8/18/2016 7:41:56 AM
First Patient Enrolled Under Newly Modified Protocol In CytoDyn (CYDY)’s Phase III PRO 140 Combination Study In HIV 7/26/2016 7:44:13 AM
CytoDyn (CYDY) Submits Orphan Drug Application To FDA For Pretreatment With PRO 140 Of Treatment-Naïve HIV Patients 7/21/2016 12:53:29 PM
CytoDyn (CYDY) Submits Protocol for Phase IIb Trial for Treatment Naïve HIV Patients 7/19/2016 8:07:28 AM
CytoDyn (CYDY) Announces Investment Community Conference Call For July 13, 2016 7/11/2016 8:19:33 AM
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn (CYDY)’s Phase IIb Monotherapy Extension Study Now Available 6/22/2016 7:43:22 AM
CytoDyn (CYDY)n’s PRO 140 Phase IIb HIV Monotherapy Trial Findings To Be Presented At ASM Microbe 2016 Conference On June 20 6/17/2016 8:08:47 AM
CytoDyn (CYDY) To Present At LD Micro Invitational Conference On June 7 6/2/2016 10:27:21 AM
Investors Aren't Impressed as Charlie Sheen Reveals He Wants in on Tiny CytoDyn (CYDY)'s HIV Drug Trial 2/12/2016 6:26:40 AM